Gilead Sciences | GILD - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 4.73B 1.08B 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
ALKERMES USD -48.28M 37.33M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amgen USD 3.83B 130M 2026-03
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.29B 856M 2026-03
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Incyte USD 324.17M 59.7M 2026-03
J&J USD 6.62B 1.03B 2026-03
Merck USD -1.88B 8.12B 2026-03
Moderna USD -1.39B 531M 2026-03
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novartis USD 4.24B 171M 2026-03
Pfizer USD 4.99B 340M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 1.94B 239M 2026-03
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
United Therapeutics USD 325.8M 340.4M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03